Go Pro
NASDAQ:BCTX

Briacell Therap Q1 2025 Earnings Report

Briacell Therap logo
$3.58 0.00 (0.00%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$3.54 -0.04 (-0.98%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Briacell Therap EPS Results

Actual EPS
-$33.00
Consensus EPS
-$12.00
Beat/Miss
Missed by -$21.00
One Year Ago EPS
N/A

Briacell Therap Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Briacell Therap Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Briacell Therap Earnings Headlines

Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
BriaCell Therapeutics Announces Closing of Offering
See More Briacell Therap Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Briacell Therap? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Briacell Therap and other key companies, straight to your email.

About Briacell Therap

Briacell Therap (NASDAQ:BCTX)eutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

View Briacell Therap Profile